Brief: SeaStar Medical Reports Positive Results For Quelimmune Therapy In Pediatric Acute Kidney Injury
22/07/2025 14:16
July 22 (Reuters) - SeaStar Medical Holding Corp ICU.O: SEASTAR MEDICAL REPORTS POSITIVE RESULTS FOR QUELIMMUNE THERAPY IN PEDIATRIC ACUTE KIDNEY INJURY (AKI) FROM THE FIRST 20 SAVE SURVEILLANCE REGISTRY PATIENTS SEASTAR MEDICAL: SAVE SURVEILLANCE REGISTRY NEW DATA ON TRACK TO VALIDATE/POTENTIALLY EXCEED 50% REDUCTION IN LOSS OF LIFE VERSUS HISTORICAL DATA Source text: ID:nGNX5MD78Q Further company coverage: ICU.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on SeaStar Medical Holding
See all newsBrief: FDA Grants Seastar Medical Breakthrough Device Designation For Its Scd Therapy For The Treatment Of Hyperinflammation In Adult Patients With Sepsis Or A Septic Condition
SeaStar Medical Holding Corp reports results for the quarter ended June 30 - Earnings Summary
SeaStar Medical Q2 revenue jumps 82% on QUELIMMUNE demand
Brief: SeaStar Medical Q2 EPS USD -0.91
SeaStar Medical Holding Corp expected to post a loss of 97 cents a share - Earnings Preview